{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:28:26Z","timestamp":1791919706023,"version":"4.3.4"},"reference-count":102,"publisher":"Bentham Science Publishers Ltd.","issue":"7","funder":[{"DOI":"10.13039\/501100003093","name":"Ministry of Education Malaysia Fundamental Research Grant Scheme","doi-asserted-by":"publisher","award":["FRGS\/1\/2016\/STG05\/UNIM\/03\/1"],"award-info":[{"award-number":["FRGS\/1\/2016\/STG05\/UNIM\/03\/1"]}],"id":[{"id":"10.13039\/501100003093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["ACAMC"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n<jats:title>Aims:<\/jats:title>\n<jats:p>The aim of this study was to sensitize the resistant breast adenocarcinoma cells towards Tumour Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-induced apoptosis.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Breast cancer is a heterogeneous disease involving complex mechanisms. TRAIL is a potential anti-cancer candidate for targeted treatment due to its selective killing effects on neoplastic cells. Nonetheless, resistance occurs in many cancers either intrinsically or after multiple treatments.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>objective:<\/jats:title>\n<jats:p>Therefore, this research investigated whether the combination of Trichostatin A (TSA) and Zebularine (Zeb) (TZ) followed by TRAIL (TZT) could sensitize the human breast adenocarcinoma cells towards apoptosis.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>Therefore, this research investigated whether the combination of Trichostatin A (TSA) and Zebularine (Zeb) (TZ) followed by TRAIL (TZT) could sensitize the human breast adenocarcinoma cells towards apoptosis.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>The breast adenocarcinoma cells, MDA-MB-231, MCF-7 and E-MDA-MB-231 (E-cadherin re-expressed MDA-MB-231) were treated with TSA, Zeb, TZ, TRAIL and TZT. The cells were subjected to hematoxylin and eosin (H &amp; E) staining and FITC-Annexin V\/Propidium Iodide apoptosis detection prior to proteome profiling.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Based on morphological observation, apoptosis was induced in all cells treated with all treatment regimens though it was more evident for the TZT-treated cells. In the apoptosis detection analysis, TZ increased early apoptosis significantly in MDA-MB-231 and MCF-7 while TRAIL induced late apoptosis significantly in E-MDA-MB-231. Based on the proteome profiling on MDA-MB-231, TRAIL R2 and Fas expression was increased. For E-MDA-MB-231, down-regulation of catalase, paraoxonase-2 (PON2), clusterin, an inhibitor of apoptosis proteins (IAPs) and cell stress proteins validated the notion that E-cadherin re-expression enhances TZT anti-cancer efficacy. Similar trend was observed in MCF-7 whereby TZT treatment down-regulated the anti-apoptotic catalase and PON2, increased the pro-apoptotic, B cell lymphoma 2 (Bcl-2)-associated agonist of cell death (Bad) and Bcl-2-associated X (Bax), second mitochondria-derived activator of caspase (SMAC) and HtrA serine peptidase 2 (HTRA2) as well as TRAIL receptors (TRAIL R1 and TRAIL R2).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>TZ treatment serves as an efficient treatment regimen for MDA-MB-231 and MCF-7, while TRAIL serves as a better treatment option for E-MDA-MB-231.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>other:<\/jats:title>\n<jats:p>Therefore, future studies on E-cadherin\u2019s positive regulatory role in TRAIL-induced apoptosis are definitely warranted.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Other:<\/jats:title>\n<jats:p>Therefore, future studies on E-cadherin\u2019s positive regulatory role in TRAIL-induced apoptosis are warranted.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1871520623666221114095733","type":"journal-article","created":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T04:28:36Z","timestamp":1668572916000},"page":"817-831","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Trailing TRAIL Resistance in Human Breast Adenocarcinoma Cells with Trichostatin\nA and Zebularine"],"prefix":"10.2174","volume":"23","author":[{"given":"Siew Ching","family":"Ngai","sequence":"first","affiliation":[{"name":"School of Biosciences, Faculty of Science and Engineering, University of Nottingham Malaysia, 43500 Semenyih, Selangor, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia How Ming","family":"Wong","sequence":"additional","affiliation":[{"name":"School of Biosciences, Faculty of Science and Engineering, University of Nottingham Malaysia, 43500 Semenyih, Selangor, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chee-Mun","family":"Fang","sequence":"additional","affiliation":[{"name":"Division of Biomedical Sciences, School of Pharmacy, Faculty of Science and Engineering, University of Nottingham Malaysia,\n43500 Semenyih, Selangor, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwei-San","family":"Loh","sequence":"additional","affiliation":[{"name":"School of Biosciences, Faculty of Science and Engineering, University of Nottingham Malaysia, 43500 Semenyih, Selangor, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1179066018790259","DOI":"10.1177\/1179066018790259","volume":"11","author":"Pandey S.S.","year":"2018","unstructured":"Pandey S.S.; Singh S.; Pathak C.; Tiwari B.S.; Programmed cell death: A process of death for survival-How far terminology pertinent for cell death in unicellular organisms. J Cell Death 2018,11,1179066018790259","journal-title":"J Cell Death"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41392-018-0018-5","volume":"3","author":"Chen Q.","year":"2018","unstructured":"Chen Q.; Kang J.; Fu C.; The independence of and associations among apoptosis, autophagy, and necrosis. Signal Transduct Target Ther 2018,3(1),18","journal-title":"Signal Transduct Target Ther"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.molmed.2013.08.007","volume":"19","author":"Stuckey D.W.","year":"2013","unstructured":"Stuckey D.W.; Shah K.; TRAIL on trial: Preclinical advances in cancer therapy. Trends Mol Med 2013,19(11),685-694","journal-title":"Trends Mol Med"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1023\/A:1011336726649","volume":"6","author":"Nagane M.","year":"2001","unstructured":"Nagane M.; Huang H.J.S.; Cavenee W.K.; The potential of TRAIL for cancer chemotherapy. Apoptosis 2001,6(3),191-197","journal-title":"Apoptosis"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"6714","DOI":"10.2174\/1381612820666140929100735","volume":"20","author":"Wang F.","year":"2014","unstructured":"Wang F.; Lin J.; Xu R.; The molecular mechanisms of TRAIL resistance in cancer cells: Help in designing new drugs. Curr Pharm Des a2014,20(42),6714-6722","journal-title":"Curr Pharm Des"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/sj.neo.7900270","volume":"4","author":"&#xD6;z&#xF6;ren N.","year":"2002","unstructured":"&#xD6;z&#xF6;ren N.; El-Deiry W.S.; Defining characteristics of Types I and II apoptotic cells in response to TRAIL. Neoplasia 2002,4(6),551-557","journal-title":"Neoplasia"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s11060-007-9472-6","volume":"86","author":"Hetschko H.","year":"2008","unstructured":"Hetschko H.; Voss V.; Horn S.; Seifert V.; Prehn J.H.M.; K&#xF6;gel D.; Pharmacological inhibition of Bcl-2 family members reactivates TRAIL-induced apoptosis in malignant glioma. J Neurooncol 2008,86(3),265-272","journal-title":"J Neurooncol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1158\/1078-0432.CCR-08-1575","volume":"15","author":"Huang S.","year":"2009","unstructured":"Huang S.; Okumura K.; Sinicrope F.A.; BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells. Clin Cancer Res 2009,15(1),150-159","journal-title":"Clin Cancer Res"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s00432-012-1187-1","volume":"138","author":"Kisim A.","year":"2012","unstructured":"Kisim A.; Atmaca H.; Cakar B.; Karabulut B.; Sezgin C.; Uzunoglu S.; Uslu R.; Karaca B.; Pretreatment with AT-101 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of breast cancer cells by inducing death receptors 4 and 5 protein levels. J Cancer Res Clin Oncol 2012,138(7),1155-1163","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"833","DOI":"10.18632\/oncotarget.542","volume":"3","author":"Chen J.J.","year":"2012","unstructured":"Chen J.J.; Shen H.C.J.; Rivera Rosado L.A.; Zhang Y.; Di X.; Zhang B.; Mislocalization of death receptors correlates with cellular resistance to their cognate ligands in human breast cancer cells. Oncotarget 2012,3(8),833-842","journal-title":"Oncotarget"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s10549-008-9924-5","volume":"113","author":"Rahman M.","year":"2009","unstructured":"Rahman M.; Davis S.R.; Pumphrey J.G.; Bao J.; Nau M.M.; Meltzer P.S.; Lipkowitz S.; TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype. Breast Cancer Res Treat 2009,113(2),217-230","journal-title":"Breast Cancer Res Treat"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.critrevonc.2019.08.008","volume":"143","author":"Wong S.H.M.","year":"2019","unstructured":"Wong S.H.M.; Kong W.Y.; Fang C.M.; Loh H.S.; Chuah L.H.; Abdullah S.; Ngai S.C.; The TRAIL to cancer therapy: Hindrances and potential solutions. Crit Rev Oncol Hematol 2019,143,81-94","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.molcel.2014.04.029","volume":"54","author":"Lu M.","year":"2014","unstructured":"Lu M.; Marsters S.; Ye X.; Luis E.; Gonzalez L.; Ashkenazi A.; E-cadherin couples death receptors to the cytoskeleton to regulate apoptosis. Mol Cell 2014,54(6),987-998","journal-title":"Mol Cell"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nrc2889","volume":"10","author":"Gyrd-Hansen M.","year":"2010","unstructured":"Gyrd-Hansen M.; Meier P.; IAPs: from caspase inhibitors to modulators of NF-&#x3BA;B, inflammation and cancer. Nat Rev Cancer 2010,10(8),561-574","journal-title":"Nat Rev Cancer"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"a008730","DOI":"10.1101\/cshperspect.a008730","volume":"5","author":"Silke J.","year":"2013","unstructured":"Silke J.; Meier P.; Inhibitor of apoptosis (IAP) proteins-modulators of cell death and inflammation. Cold Spring Harb Perspect Biol 2013,5(2),a008730","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1158\/1535-7163.MCT-11-0787","volume":"11","author":"Allensworth J.L.","year":"2012","unstructured":"Allensworth J.L.; Aird K.M.; Aldrich A.J.; Batinic-Haberle I.; Devi G.R.; XIAP inhibition and generation of reactive oxygen species enhances TRAIL sensitivity in inflammatory breast cancer cells. Mol Cancer Ther 2012,11(7),1518-1527","journal-title":"Mol Cancer Ther"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1002\/ijc.22554","volume":"120","author":"Lopes R.B.","year":"2007","unstructured":"Lopes R.B.; Gangeswaran R.; McNeish I.A.; Wang Y.; Lemoine N.R.; Expression of the IAP protein family is dysregulated in pancreatic cancer cells and is important for resistance to chemotherapy. Int J Cancer 2007,120(11),2344-2352","journal-title":"Int J Cancer"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s00280-014-2465-1","volume":"73","author":"Azijli K.","year":"2014","unstructured":"Azijli K.; van Roosmalen I.A.M.; Smit J.; Pillai S.; Fukushima M.; de Jong S.; Peters G.J.; Bijnsdorp I.V.; Kruyt F.A.E.; The novel thymidylate synthase inhibitor trifluorothymidine (TFT) and TRAIL synergistically eradicate non-small cell lung cancer cells. Cancer Chemother Pharmacol 2014,73(6),1273-1283","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1159\/000151511","volume":"120","author":"Conticello C.","year":"2008","unstructured":"Conticello C.; Adamo L.; Vicari L.; Giuffrida R.; Iannolo G.; Anastasi G.; Caruso L.; Moschetti G.; Cupri A.; Palumbo G.A.; Gulisano M.; De Maria R.; Giustolisi R.; Di Raimondo F.; Antitumor activity of bortezomib alone and in combination with TRAIL in human acute myeloid leukemia. Acta Haematol 2008,120(1),19-30","journal-title":"Acta Haematol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"4943","DOI":"10.1074\/jbc.M609494200","volume":"282","author":"Li H.","year":"2007","unstructured":"Li H.; Wang X.; Li N.; Qiu J.; Zhang Y.; Cao X.; hPEBP4 resists TRAIL-induced apoptosis of human prostate cancer cells by activating Akt and deactivating ERK1\/2 pathways. J Biol Chem 2007,282(7),4943-4950","journal-title":"J Biol Chem"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/cdd.2017.143","volume":"25","author":"Castrogiovanni C.","year":"2018","unstructured":"Castrogiovanni C.; Waterschoot B.; De Backer O.; Dumont P.; Serine 392 phosphorylation modulates p53 mitochondrial translocation and transcription-independent apoptosis. Cell Death Differ 2018,25(1),190-203","journal-title":"Cell Death Differ"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"51482","DOI":"10.18632\/oncotarget.9856","volume":"7","author":"Wu S.Y.","year":"2016","unstructured":"Wu S.Y.; Wu A.T.H.; Liu S.H.; Wu S.Y.; Wu A.T.H.; Liu S-H.; MicroRNA-17-5p regulated apoptosis-related protein expression and radiosensitivity in oral squamous cell carcinoma caused by betel nut chewing. Oncotarget 2016,7(32),51482-51493","journal-title":"Oncotarget"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.4161\/cbt.4.10.2255","volume":"4","author":"Mayes P.A.","year":"2005","unstructured":"Mayes P.A.; Campbell L.; Ricci M.S.; Plastaras J.P.; Dicker D.T.; El-Deiry W.S.; Modulation of TRAIL-induced tumor cell apoptosis in a hypoxic environment. Cancer Biol Ther 2005,4(10),1068-1074","journal-title":"Cancer Biol Ther"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3892\/ijo.2014.2399","volume":"45","author":"Wang X.","year":"2014","unstructured":"Wang X.; Chen M.; Zhou J.; Zhang X.; HSP27, 70 and 90, anti-apoptotic proteins, in clinical cancer therapy. Int J Oncol b2014,45(1),18-30","journal-title":"Int J Oncol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.35118\/apjmbb.2021.029.1.04","volume":"29","author":"Wong S.H.M.","year":"2021","unstructured":"Wong S.H.M.; Fang C.M.; Loh H.S.; Ngai S.C.; Trichostatin A and Zebularine along with E-cadherin re-expression enhance tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cell cycle arrest in human breast adenocarcinoma cells. Asia Pac J Mol Biol Biotechnol 2021,29(1),26-41","journal-title":"Asia Pac J Mol Biol Biotechnol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"e02468","DOI":"10.1016\/j.heliyon.2019.e02468","volume":"5","author":"Kong W.Y.","year":"2019","unstructured":"Kong W.Y.; Yee Z.Y.; Mai C.W.; Fang C.M.; Abdullah S.; Ngai S.C.; Zebularine and trichostatin A sensitized human breast adenocarcinoma cells towards tumor necrosis factor-related apoptosis inducing ligand (TRAIL)-induced apoptosis. Heliyon 2019,5(9),e02468","journal-title":"Heliyon"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"25798","DOI":"10.1038\/srep25798","volume":"6","author":"Pan Y.","year":"2016","unstructured":"Pan Y.; Li J.; Zhang Y.; Wang N.; Liang H.; Liu Y.; Zhang C.Y.; Zen K.; Gu H.; Slug-upregulated miR-221 promotes breast cancer progression through suppressing E-cadherin expression. Sci Rep 2016,6(1),25798","journal-title":"Sci Rep"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"e2058","DOI":"10.1038\/cddis.2015.275","volume":"7","author":"Baig S.","year":"2016","unstructured":"Baig S.; Seevasant I.; Mohamad J.; Mukheem A.; Huri H.Z.; Kamarul T.; Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand? Cell Death Dis 2016,7(1),e2058","journal-title":"Cell Death Dis"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1080\/01926230701320337","volume":"35","author":"Elmore S.","year":"2007","unstructured":"Elmore S.; Apoptosis: a review of programmed cell death. Toxicol Pathol 2007,35(4),495-516","journal-title":"Toxicol Pathol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/35070009","volume":"3","author":"Coleman M.L.","year":"2001","unstructured":"Coleman M.L.; Sahai E.A.; Yeo M.; Bosch M.; Dewar A.; Olson M.F.; Membrane blebbing during apoptosis results from caspase-mediated activation of ROCK I. Nat Cell Biol 2001,3(4),339-345","journal-title":"Nat Cell Biol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/S0008-6363(99)00384-3","volume":"45","author":"Saraste A.","year":"2000","unstructured":"Saraste A.; Pulkki K.; Morphologic and biochemical hallmarks of apoptosis. Cardiovasc Res 2000,45(3),528-537","journal-title":"Cardiovasc Res"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.31557\/APJCP.2020.21.6.1819","volume":"21","author":"Sanaei M.","year":"2020","unstructured":"Sanaei M.; Kavoosi F.; Investigation of the effect of zebularine in comparison to and in combination with trichostatin A on p21Cip1\/Waf1\/Sdi1, p27Kip1, p57Kip2, DNA methyltransferases and histone deacetylases in colon cancer LS 180 Cell Line. Asian Pac J Cancer Prev 2020,21(6),1819-1828","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s10549-009-0420-3","volume":"120","author":"Billam M.","year":"2010","unstructured":"Billam M.; Sobolewski M.D.; Davidson N.E.; Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells. Breast Cancer Res Treat 2010,120(3),581-592","journal-title":"Breast Cancer Res Treat"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"e54036","DOI":"10.1371\/journal.pone.0054036","volume":"8","author":"Nakamura K.","year":"2013","unstructured":"Nakamura K.; Aizawa K.; Nakabayashi K.; Kato N.; Yamauchi J.; Hata K.; Tanoue A.; DNA methyltransferase inhibitor zebularine inhibits human hepatic carcinoma cells proliferation and induces apoptosis. PLoS One 2013,8(1),e54036","journal-title":"PLoS One"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1002\/mc.22042","volume":"53","author":"You B.R.","year":"2014","unstructured":"You B.R.; Park W.H.; Zebularine inhibits the growth of A549 lung cancer cells via cell cycle arrest and apoptosis. Mol Carcinog 2014,53(11),847-857","journal-title":"Mol Carcinog"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1476-4598-5-8","volume":"5","author":"Alao J.P.","year":"2006","unstructured":"Alao J.P.; Stavropoulou A.V.; Lam E.W.F.; Charles Coombes R.; Vigushin D.M.; Histone deacetylase inhibitor, Trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells. Mol Cancer 2006,5(1),8","journal-title":"Mol Cancer"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"e91610","DOI":"10.1371\/journal.pone.0091610","volume":"9","author":"Sun S.","year":"2014","unstructured":"Sun S.; Han Y.; Liu J.; Fang Y.; Tian Y.; Zhou J.; Ma D.; Wu P.; Trichostatin A targets the mitochondrial respiratory chain, increasing mitochondrial reactive oxygen species production to trigger apoptosis in human breast cancer cells. PLoS One 2014,9(3),e91610","journal-title":"PLoS One"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1126\/science.1133289","volume":"315","author":"Willis S.N.","year":"2007","unstructured":"Willis S.N.; Fletcher J.I.; Kaufmann T.; van Delft M.F.; Chen L.; Czabotar P.E.; Ierino H.; Lee E.F.; Fairlie W.D.; Bouillet P.; Strasser A.; Kluck R.M.; Adams J.M.; Huang D.C.S.; Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 2007,315(5813),856-859","journal-title":"Science"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.1093\/nar\/gkn356","volume":"36","author":"Makki M.S.","year":"2008","unstructured":"Makki M.S.; Heinzel T.; Englert C.; TSA downregulates Wilms tumor gene 1 (Wt1) expression at multiple levels. Nucleic Acids Res 2008,36(12),4067-4078","journal-title":"Nucleic Acids Res"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/BF02479423","volume":"18","author":"Sawa H.","year":"2001","unstructured":"Sawa H.; Murakami H.; Ohshima Y.; Sugino T.; Nakajyo T.; Kisanuki T.; Tamura Y.; Satone A.; Ide W.; Hashimoto I.; Kamada H.; Histone deacetylase inhibitors such as sodium butyrate and trichostatin A induce apoptosis through an increase of the bcl-2-related protein Bad. Brain Tumor Pathol 2001,18(2),109-114","journal-title":"Brain Tumor Pathol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.1158\/0008-5472.CAN-03-3970","volume":"64","author":"Pompeia C.","year":"2004","unstructured":"Pompeia C.; Hodge D.R.; Plass C.; Wu Y.Z.; Marquez V.E.; Kelley J.A.; Farrar W.L.; Microarray analysis of epigenetic silencing of gene expression in the KAS-6\/1 multiple myeloma cell line. Cancer Res 2004,64(10),3465-3473","journal-title":"Cancer Res"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.2174\/1871520621666210608103251","volume":"22","author":"Yap Z.H.","year":"2022","unstructured":"Yap Z.H.; Kong W.Y.; Azeez A.R.; Fang C.M.; Ngai S.C.; Anti-cancer effects of epigenetics drugs scriptaid and zebularine in human breast adenocarcinoma cells. Anticancer Agents Med Chem 2022,22(8),1582-1591","journal-title":"Anticancer Agents Med Chem"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/emm.2006.73","volume":"38","author":"Kim H.R.","year":"2006","unstructured":"Kim H.R.; Kim E.J.; Yang S.H.; Jeong E.T.; Park C.; Lee J.H.; Youn M.J.; So H.S.; Park R.; Trichostatin A induces apoptosis in lung cancer cells via simultaneous activation of the death receptor-mediated and mitochondrial pathway. Exp Mol Med 2006,38(6),616-624","journal-title":"Exp Mol Med"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S1535-6108(02)00095-8","volume":"2","author":"Maecker H.L.","year":"2002","unstructured":"Maecker H.L.; Yun Z.; Maecker H.T.; Giaccia A.J.; Epigenetic changes in tumor Fas levels determine immune escape and response to therapy. Cancer Cell 2002,2(2),139-148","journal-title":"Cancer Cell"},{"key":"ref=45","first-page":"1052","volume":"33","author":"Morinobu A.","year":"2006","unstructured":"Morinobu A.; Wang B.; Liu J.; Yoshiya S.; Kurosaka M.; Kumagai S.; Trichostatin A cooperates with Fas-mediated signal to induce apoptosis in rheumatoid arthritis synovial fibroblasts. J Rheumatol 2006,33(6),1052-1060","journal-title":"J Rheumatol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"7381","DOI":"10.1038\/sj.onc.1208888","volume":"24","author":"Bockbrader K.M.","year":"2005","unstructured":"Bockbrader K.M.; Tan M.; Sun Y.; A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells. Oncogene 2005,24(49),7381-7388","journal-title":"Oncogene"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1158\/1535-7163.MCT-13-0153","volume":"13","author":"Finlay D.","year":"2014","unstructured":"Finlay D.; Vamos M.; Gonz&#xE1;lez-L&#xF3;pez M.; Ardecky R.J.; Ganji S.R.; Yuan H.; Su Y.; Cooley T.R.; Hauser C.T.; Welsh K.; Reed J.C.; Cosford N.D.P.; Vuori K.; Small-molecule IAP antagonists sensitize cancer cells to TRAIL-induced apoptosis: roles of XIAP and cIAPs. Mol Cancer Ther 2014,13(1),5-15","journal-title":"Mol Cancer Ther"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"31","DOI":"10.4062\/biomolther.2014.092","volume":"23","author":"Han M.H.","year":"2015","unstructured":"Han M.H.; Park C.; Kwon T.K.; Kim G.Y.; Kim W.J.; Hong S.H.; Yoo Y.H.; Choi Y.H.; The histone deacetylase inhibitor trichostatin A sensitizes human renal carcinoma cells to TRAIL-induced apoptosis through down-regulation of c-FLIPL. Biomol Ther (Seoul) 2015,23(1),31-38","journal-title":"Biomol Ther (Seoul)"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3892\/ijo.2012.1546","volume":"41","author":"Shin D.Y.","year":"2012","unstructured":"Shin D.Y.; Park Y.S.; Yang K.; Kim G.Y.; Kim W.J.; Han M.H.; Kang H.S.; Choi Y.H.; Decitabine, a DNA methyltransferase inhibitor, induces apoptosis in human leukemia cells through intracellular reactive oxygen species generation. Int J Oncol 2012,41(3),910-918","journal-title":"Int J Oncol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S0300-483X(02)00460-2","volume":"181-182","author":"Pietenpol J.A.","year":"2002","unstructured":"Pietenpol J.A.; Stewart Z.A.; Cell cycle checkpoint signaling. Toxicology 2002,181-182,475-481","journal-title":"Toxicology"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.3892\/mmr.2013.1650","volume":"8","author":"Wang L.","year":"2013","unstructured":"Wang L.; Wang G.; Yang D.; Guo X.; Xu Y.; Feng B.; Kang J.; Euphol arrests breast cancer cells at the G1 phase through the modulation of cyclin D1, p21 and p27 expression. Mol Med Rep b2013,8(4),1279-1285","journal-title":"Mol Med Rep"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1593\/neo.04655","volume":"7","author":"Fandy T.E.","year":"2005","unstructured":"Fandy T.E.; Shankar S.; Ross D.D.; Sausville E.; Srivastava R.K.; Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia 2005,7(7),646-657","journal-title":"Neoplasia"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.yexcr.2004.04.038","volume":"298","author":"Chopin V.","year":"2004","unstructured":"Chopin V.; Slomianny C.; Hondermarck H.; Le Bourhis X.; Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors\u2019 signaling and requires P21waf1. Exp Cell Res 2004,298(2),560-573","journal-title":"Exp Cell Res"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1074\/jbc.M408063200","volume":"280","author":"Varshochi R.","year":"2005","unstructured":"Varshochi R.; Halim F.; Sunters A.; Alao J.P.; Madureira P.A.; Hart S.M.; Ali S.; Vigushin D.M.; Coombes R.C.; Lam E.W.F.; ICI182,780 induces p21Waf1 gene transcription through releasing histone deacetylase 1 and estrogen receptor alpha from Sp1 sites to induce cell cycle arrest in MCF-7 breast cancer cell line. J Biol Chem 2005,280(5),3185-3196","journal-title":"J Biol Chem"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.3892\/or.2014.3107","volume":"31","author":"Zuo X.","year":"2014","unstructured":"Zuo X.; Qin Y.; Zhang X.; Ning Q.; Shao S.; Luo M.; Yuan N.; Huang S.; Zhao X.; Breast cancer cells are arrested at different phases of the cell cycle following the re-expression of ARHI. Oncol Rep 2014,31(5),2358-2364","journal-title":"Oncol Rep"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1186\/s12885-016-2807-y","volume":"16","author":"Hrgovic I.","year":"2016","unstructured":"Hrgovic I.; Doll M.; Kleemann J.; Wang X.F.; Zoeller N.; Pinter A.; Kippenberger S.; Kaufmann R.; Meissner M.; The histone deacetylase inhibitor trichostatin a decreases lymphangiogenesis by inducing apoptosis and cell cycle arrest via p21-dependent pathways. BMC Cancer 2016,16(1),763","journal-title":"BMC Cancer"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"21294","DOI":"10.1074\/jbc.M710539200","volume":"283","author":"Pietsch E.C.","year":"2008","unstructured":"Pietsch E.C.; Perchiniak E.; Canutescu A.A.; Wang G.; Dunbrack R.L.; Murphy M.E.; Oligomerization of BAK by p53 utilizes conserved residues of the p53 DNA binding domain. J Biol Chem 2008,283(30),21294-21304","journal-title":"J Biol Chem"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"7305","DOI":"10.1038\/sj.onc.1209735","volume":"25","author":"Hui L.","year":"2006","unstructured":"Hui L.; Zheng Y.; Yan Y.; Bargonetti J.; Foster D.A.; Mutant p53 in MDA-MB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phospholipase D. Oncogene 2006,25(55),7305-7310","journal-title":"Oncogene"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1136\/jcp.2003.015032","volume":"57","author":"Greijer A.E.","year":"2004","unstructured":"Greijer A.E.; van der Wall E.; The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol 2004,57(10),1009-1014","journal-title":"J Clin Pathol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S0006-2952(02)01155-3","volume":"64","author":"Piret J.P.","year":"2002","unstructured":"Piret J.P.; Mottet D.; Raes M.; Michiels C.; Is HIF-1&#x3B1; a pro- or an anti-apoptotic protein? Biochem Pharmacol 2002,64(5-6),889-892","journal-title":"Biochem Pharmacol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1038\/cddis.2011.48","volume":"2","author":"Sermeus A.","year":"2011","unstructured":"Sermeus A.; Michiels C.; Reciprocal influence of the p53 and the hypoxic pathways. Cell Death Dis 2011,2(5),e164","journal-title":"Cell Death Dis"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2010\/214074","volume":"2010","author":"Fulda S.","year":"2010","unstructured":"Fulda S.; Gorman A.M.; Hori O.; Samali A.; Cellular stress responses: Cell survival and cell death. Int J Cell Biol 2010,2010,1-23","journal-title":"Int J Cell Biol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"25088","DOI":"10.1074\/jbc.M701740200","volume":"282","author":"Voss O.H.","year":"2007","unstructured":"Voss O.H.; Batra S.; Kolattukudy S.J.; Gonzalez-Mejia M.E.; Smith J.B.; Doseff A.I.; Binding of caspase-3 prodomain to heat shock protein 27 regulates monocyte apoptosis by inhibiting caspase-3 proteolytic activation. J Biol Chem 2007,282(34),25088-25099","journal-title":"J Biol Chem"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1093\/hmg\/ddr469","volume":"21","author":"Ferreira A.C.","year":"2012","unstructured":"Ferreira A.C.; Suriano G.; Mendes N.; Gomes B.; Wen X.; Carneiro F.; Seruca R.; Machado J.C.; E-cadherin impairment increases cell survival through notch-dependent upregulation of Bcl-2. Hum Mol Genet 2012,21(2),334-343","journal-title":"Hum Mol Genet"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/(SICI)1097-0215(20000601)86:5<660:AID-IJC9>3.0.CO;2-X","volume":"86","author":"Sasaki C.Y.","year":"2000","unstructured":"Sasaki C.Y.; Lin H.; Passaniti A.; Expression of E-cadherin reduces Bcl-2 expression and increases sensitivity to etoposide-induced apoptosis. Int J Cancer 2000,86(5),660-666","journal-title":"Int J Cancer"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1080\/cac.10.2.105.118","volume":"10","author":"Fedor-Chaiken M.","year":"2003","unstructured":"Fedor-Chaiken M.; Hein P.W.; Stewart J.C.; Brackenbury R.; Kinch M.S.; E-cadherin binding modulates EGF receptor activation. Cell Commun Adhes 2003,10(2),105-118","journal-title":"Cell Commun Adhes"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1210\/me.2004-0342","volume":"19","author":"Reddy P.","year":"2005","unstructured":"Reddy P.; Liu L.; Ren C.; Lindgren P.; Boman K.; Shen Y.; Lundin E.; Ottander U.; Rytinki M.; Liu K.; Formation of E-cadherin-mediated cell-cell adhesion activates AKT and mitogen activated protein kinase via phosphatidylinositol 3 kinase and ligand-independent activation of epidermal growth factor receptor in ovarian cancer cells. Mol Endocrinol 2005,19(10),2564-2578","journal-title":"Mol Endocrinol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/S0002-9440(10)63390-1","volume":"165","author":"Shen X.","year":"2004","unstructured":"Shen X.; Kramer R.H.; Adhesion-mediated squamous cell carcinoma survival through ligand-independent activation of epidermal growth factor receptor. Am J Pathol 2004,165(4),1315-1329","journal-title":"Am J Pathol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"27643","DOI":"10.1074\/jbc.M108863200","volume":"277","author":"Gilmore A.P.","year":"2002","unstructured":"Gilmore A.P.; Valentijn A.J.; Wang P.; Ranger A.M.; Bundred N.; O\u2019Hare M.J.; Wakeling A.; Korsmeyer S.J.; Streuli C.H.; Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor. J Biol Chem 2002,277(31),27643-27650","journal-title":"J Biol Chem"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"459","DOI":"10.2174\/138920310791824057","volume":"11","author":"Chen D.","year":"2010","unstructured":"Chen D.; Ping Dou.Q; The ubiquitin-proteasome system as a prospective molecular target for cancer treatment and prevention. Curr Protein Pept Sci 2010,11(6),459-470","journal-title":"Curr Protein Pept Sci"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"3850","DOI":"10.1073\/pnas.070047997","volume":"97","author":"Li B.","year":"2000","unstructured":"Li B.; Dou Q.P.; Bax degradation by the ubiquitin\/proteasome-dependent pathway: Involvement in tumor survival and progression. Proc Natl Acad Sci USA 2000,97(8),3850-3855","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1073\/pnas.1615072114","volume":"114","author":"Reis C.R.","year":"2017","unstructured":"Reis C.R.; Chen P.H.; Bendris N.; Schmid S.L.; TRAIL-death receptor endocytosis and apoptosis are selectively regulated by dynamin-1 activation. Proc Natl Acad Sci USA 2017,114(3),504-509","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"917","DOI":"10.4161\/cbt.8.10.8141","volume":"8","author":"Zhang Y.","year":"2009","unstructured":"Zhang Y.; Yoshida T.; Zhang B.; TRAIL induces endocytosis of its death receptors in MDA-MB-231 breast cancer cells. Cancer Biol Ther 2009,8(10),917-922","journal-title":"Cancer Biol Ther"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1093\/carcin\/bgt484","volume":"35","author":"Jalving M.","year":"2014","unstructured":"Jalving M.; Heijink D.M.; Koornstra J.J.; Boersma-van Ek W.; Zwart N.; Wesseling J.; Sluiter W.J.; de Vries E.G.E.; Kleibeuker J.H.; de Jong S.; Regulation of TRAIL receptor expression by -catenin in colorectal tumours. Carcinogenesis 2014,35(5),1092-1099","journal-title":"Carcinogenesis"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.critrevonc.2017.11.010","volume":"121","author":"Wong S.H.M.","year":"2018","unstructured":"Wong S.H.M.; Fang C.M.; Chuah L.H.; Leong C.O.; Ngai S.C.; E-cadherin: Its dysregulation in carcinogenesis and clinical implications. Crit Rev Oncol Hematol 2018,121,11-22","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1126\/science.1109083","volume":"308","author":"Essers M.A.G.","year":"2005","unstructured":"Essers M.A.G.; de Vries-Smits L.M.M.; Barker N.; Polderman P.E.; Burgering B.M.T.; Korswagen H.C.; Functional interaction between beta-catenin and FOXO in oxidative stress signaling. Science 2005,308(5725),1181-1184","journal-title":"Science"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1006\/bbrc.1999.1002","volume":"261","author":"Hiscox S.","year":"1999","unstructured":"Hiscox S.; Jiang W.G.; Association of the HGF\/SF receptor, c-met, with the cell-surface adhesion molecule, E-cadherin, and catenins in human tumor cells. Biochem Biophys Res Commun 1999,261(2),406-411","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1006\/bbrc.1995.1443","volume":"208","author":"Kanai Y.","year":"1995","unstructured":"Kanai Y.; Ochiai A.; Shibata T.; Oyama T.; Ushijima S.; Akimoto S.; Hirohashi S.; c-erbB-2 gene product directly associates with &#x3B2;-catenin and plakoglobin. Biochem Biophys Res Commun 1995,208(3),1067-1072","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"7216","DOI":"10.1128\/MCB.18.12.7216","volume":"18","author":"Li Y.","year":"1998","unstructured":"Li Y.; Bharti A.; Chen D.; Gong J.; Kufe D.; Interaction of glycogen synthase kinase 3beta with the DF3\/MUC1 carcinoma-associated antigen and beta-catenin. Mol Cell Biol 1998,18(12),7216-7224","journal-title":"Mol Cell Biol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1023\/A:1015312119693","volume":"7","author":"Grossmann J.","year":"2002","unstructured":"Grossmann J.; Molecular mechanisms of &#x201C;detachment-induced apoptosis--Anoikis&#x201D;. Apoptosis 2002,7(3),247-260","journal-title":"Apoptosis"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1038\/emm.2014.99","volume":"47","author":"Kim R.K.","year":"2015","unstructured":"Kim R.K.; Suh Y.; Yoo K.C.; Cui Y.H.; Kim H.; Kim M.J.; Gyu Kim I.; Lee S.J.; Activation of KRAS promotes the mesenchymal features of basal-type breast cancer. Exp Mol Med 2015,47(1),e137","journal-title":"Exp Mol Med"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"a031492","DOI":"10.1101\/cshperspect.a031492","volume":"8","author":"Hymowitz S.G.","year":"2018","unstructured":"Hymowitz S.G.; Malek S.; Targeting the MAPK pathway in RAS mutant cancers. Cold Spring Harb Perspect Med 2018,8(11),a031492","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4061\/2011\/219309","volume":"2011","author":"Sullivan K.M.","year":"2011","unstructured":"Sullivan K.M.; Kozuch P.S.; Impact of KRAS mutations on management of colorectal carcinoma. Pathol Res Int 2011,2011,1-11","journal-title":"Pathol Res Int"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s12307-011-0085-4","volume":"5","author":"Chao Y.","year":"2012","unstructured":"Chao Y.; Wu Q.; Acquafondata M.; Dhir R.; Wells A.; Partial mesenchymal to epithelial reverting transition in breast and prostate cancer metastases. Cancer Microenviron 2012,5(1),19-28","journal-title":"Cancer Microenviron"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/1476-4598-9-179","volume":"9","author":"Chao Y.L.","year":"2010","unstructured":"Chao Y.L.; Shepard C.R.; Wells A.; Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition. Mol Cancer 2010,9(1),179","journal-title":"Mol Cancer"},{"key":"ref=86","first-page":"11752","volume":"8","author":"Chen L.","year":"2015","unstructured":"Chen L.; Jian W.; Lu L.; Zheng L.; Yu Z.; Zhou D.; Elevated expression of E-cadherin in primary breast cancer and its corresponding metastatic lymph node. Int J Clin Exp Med 2015,8(7),11752-11758","journal-title":"Int J Clin Exp Med"},{"key":"ref=87","first-page":"23","volume":"1826","author":"Rodriguez F.J.","year":"2012","unstructured":"Rodriguez F.J.; Lewis-Tuffin L.J.; Anastasiadis P.Z.; E-cadherin\u2019s dark side: possible role in tumor progression. Biochim Biophys Acta 2012,1826(1),23-31","journal-title":"Biochim Biophys Acta"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.canlet.2014.02.001","volume":"347","author":"Al-Rayyan N.","year":"2014","unstructured":"Al-Rayyan N.; Litchfield L.M.; Ivanova M.M.; Radde B.N.; Cheng A.; Elbedewy A.; Klinge C.M.; 5-Aza-2-deoxycytidine and trichostatin A increase COUP-TFII expression in antiestrogen-resistant breast cancer cell lines. Cancer Lett 2014,347(1),139-150","journal-title":"Cancer Lett"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1158\/1541-7786.MCR-08-0313","volume":"6","author":"Zhang Y.","year":"2008","unstructured":"Zhang Y.; Zhang B.; TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5. Mol Cancer Res 2008,6(12),1861-1871","journal-title":"Mol Cancer Res"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"R217","DOI":"10.1186\/bcr651","volume":"5","author":"Kowalski P.J.","year":"2003","unstructured":"Kowalski P.J.; Rubin M.A.; Kleer C.G.; E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res 2003,5(6),R217-R222","journal-title":"Breast Cancer Res"},{"key":"ref=91","first-page":"759","volume":"35","author":"Fulga V.","year":"2015","unstructured":"Fulga V.; Rudico L.; Balica A.R.; Cimpean A.M.; Saptefrati L.; Margan M.M.; Raica M.; Differential expression of e-cadherin in primary breast cancer and corresponding lymph node metastases. Anticancer Res 2015,35(2),759-765","journal-title":"Anticancer Res"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"17512","DOI":"10.18632\/oncotarget.24776","volume":"9","author":"Ito F.","year":"2018","unstructured":"Ito F.; Yoshimoto C.; Yamada Y.; Sudo T.; Kobayashi H.; The HNF-1&#x3B2;-USP28-Claspin pathway upregulates DNA damage-induced Chk1 activation in ovarian clear cell carcinoma. Oncotarget 2018,9(25),17512-17522","journal-title":"Oncotarget"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.1007\/s00018-013-1307-3","volume":"70","author":"Patil M.","year":"2013","unstructured":"Patil M.; Pabla N.; Dong Z.; Checkpoint kinase 1 in DNA damage response and cell cycle regulation. Cell Mol Life Sci 2013,70(21),4009-4021","journal-title":"Cell Mol Life Sci"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"35337","DOI":"10.1074\/jbc.M506460200","volume":"280","author":"Clarke C.A.L.","year":"2005","unstructured":"Clarke C.A.L.; Bennett L.N.; Clarke P.R.; Cleavage of claspin by caspase-7 during apoptosis inhibits the Chk1 pathway. J Biol Chem 2005,280(42),35337-35345","journal-title":"J Biol Chem"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1038\/sj.cdd.4402134","volume":"14","author":"Semple J.I.","year":"2007","unstructured":"Semple J.I.; Smits V A J.; Fernaud J-R.; Mamely I.; Freire R.; Cleavage and degradation of Claspin during apoptosis by caspases and the proteasome. Cell Death Differ 2007,14(8),1433-1442","journal-title":"Cell Death Differ"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1186\/s12885-015-1441-4","volume":"15","author":"Gibbons J.A.","year":"2015","unstructured":"Gibbons J.A.; Kanwar J.R.; Kanwar R.K.; Iron-free and iron-saturated bovine lactoferrin inhibit survivin expression and differentially modulate apoptosis in breast cancer. BMC Cancer 2015,15(1),425","journal-title":"BMC Cancer"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"e17574","DOI":"10.1371\/journal.pone.0017574","volume":"6","author":"Smeenk L.","year":"2011","unstructured":"Smeenk L.; van Heeringen S.J.; Koeppel M.; Gilbert B.; Janssen-Megens E.; Stunnenberg H.G.; Lohrum M.; Role of p53 serine 46 in p53 target gene regulation. PLoS One 2011,6(3),e17574","journal-title":"PLoS One"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1038\/onc.2013.378","volume":"33","author":"Benson E.K.","year":"2014","unstructured":"Benson E.K.; Mungamuri S.K.; Attie O.; Kracikova M.; Sachidanandam R.; Manfredi J.J.; Aaronson S.A.; p53-dependent gene repression through p21 is mediated by recruitment of E2F4 repression complexes. Oncogene 2014,33(30),3959-3969","journal-title":"Oncogene"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"17192","DOI":"10.18632\/oncotarget.3780","volume":"6","author":"Wang J.","year":"2015","unstructured":"Wang J.; Guo W.; Zhou H.; Luo N.; Nie C.; Zhao X.; Yuan Z.; Liu X.; Wei Y.; Mitochondrial p53 phosphorylation induces Bak-mediated and caspase-independent cell death. Oncotarget 2015,6(19),17192-17205","journal-title":"Oncotarget"},{"key":"ref=100","first-page":"145","volume":"9","author":"Amaral J.D.","year":"2010","unstructured":"Amaral J.D.; Xavier J.M.; Steer C.J.; Rodrigues C.M.; The role of p53 in apoptosis. Discov Med 2010,9(45),145-152","journal-title":"Discov Med"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"31289","DOI":"10.1074\/jbc.M702777200","volume":"282","author":"Chandra D.","year":"2007","unstructured":"Chandra D.; Choy G.; Tang D.G.; Cytosolic accumulation of HSP60 during apoptosis with or without apparent mitochondrial release: evidence that its pro-apoptotic or pro-survival functions involve differential interactions with caspase-3. J Biol Chem 2007,282(43),31289-31301","journal-title":"J Biol Chem"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.3892\/ol.2015.3735","volume":"10","author":"Zhu X.F.","year":"2015","unstructured":"Zhu X.F.; Li W.; Ma J.Y.; Shao N.; Zhang Y.J.; Liu R.M.; Wu W.B.; Lin Y.; Wang S.M.; Knockdown of heme oxygenase-1 promotes apoptosis and autophagy and enhances the cytotoxicity of doxorubicin in breast cancer cells. Oncol Lett 2015,10(5),2974-2980","journal-title":"Oncol Lett"}],"container-title":["Anti-Cancer Agents in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871520623666221114095733","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/210867\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871520623666221114095733","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T10:28:12Z","timestamp":1680863292000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/210867\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":102,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871520623666221114095733","relation":{},"ISSN":["1871-5206"],"issn-type":[{"value":"1871-5206","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-05-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-08","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}